Roivant Sciences Accrued liabilities increased by 352.9% to $63.23M in Q1 2026 compared to the prior quarter. Over 2 years (FY 2021 to FY 2023), Accrued liabilities shows a downward trend with a -10.9% CAGR.
Fluctuations reflect changes in the timing of operational expense recognition and payment cycles.
This represents the net change in short-term obligations for expenses that have been incurred but not yet invoiced or pa...
Standard line item in the operating section of the cash flow statement.
other_increase_decrease_in_accrued_liabilities| Q1 '21 | Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q3 '24 | Q1 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$7.34M | $25.91M | $17.01M | $15.02M | -$18.18M | $19.62M | $4.26M | $33.25M | -$49.96M | $37.57M | -$3.40M | $55.94M | -$37.58M | -$3.03M | -$25.00M | $63.23M |
| QoQ Change | — | +453.0% | -34.4% | -11.7% | -221.0% | +208.0% | -78.3% | +681.5% | -250.2% | +175.2% | -109.0% | >999% | -167.2% | +91.9% | -724.3% | +352.9% |
| YoY Change | — | — | — | — | -147.6% | -24.3% | -75.0% | +121.4% | -174.9% | +91.4% | -179.8% | +68.2% | +24.8% | +10.7% | +33.5% | — |